Table 2.
Baseline characteristics of intervention and TAU cohorts
| Characteristic | Intervention (N = 23) | TAU (N = 25) |
|---|---|---|
| Sociodemographics (N [%] unless noted) | ||
| Age (years), M (SD) | 60.4 (11.7) | 65.2 (11.2) |
| Male | 12 (52) | 17 (68) |
| White | 18 (78) | 20 (80) |
| Admission diagnosis: MI | 15 (65) | 17 (68) |
| Length of stay (days), M (SD) | 3.7 (2.3) | 3.7 (2.8) |
| Married | 13 (56) | 18 (72) |
| Lives alone | 5 (22) | 3 (12) |
| Medical history | ||
| Charlson Medical Comorbidity Index, M (SD) | 2.2 (1.3) | 2.1 (1.4) |
| Body Mass Index, M (SD) | 29.3 (7.4) | 30.1 (5.3) |
| Diabetes mellitus type 2 | 4 (17) | 8 (32) |
| Current smoker | 5 (22) | 4 (16) |
| Hyperlipidemia | 17 (74) | 19 (76) |
| Hypertension(*) | 12 (52) | 19 (76) |
| Prior acute coronary syndrome | 7 (30) | 11 (44) |
| Peak troponin T (ng/ml), M (SD) | 2.2 (6.0) | 2.1 (2.9) |
| Left ventricular ejection fraction (%), M (SD) | 53.8 (13.9) | 58.6 (9.4) |
| Medications at discharge | ||
| Aspirin | 22 (96) | 25 (100) |
| Beta blocker | 22 (96) | 24 (96) |
| Angiotensin converting enzyme inhibitor/angiotensin receptor blocker | 13 (56) | 18 (72) |
| Antiplatelet agent | 21 (91) | 21 (84) |
| Statin(*) | 23 (100) | 21 (84) |
M mean, SD standard deviation
(*)
p < .10